According to data from S&P Global Market Intelligence, shares of the rare disease specialist Vertex Pharmaceuticals (NASDAQ:VRTX) rose by 16.6% last month. The drugmaker's shares appear to have benefited from both the company's presentation at the 35th annual J.P. Morgan Healthcare Conference as well as its strong fourth-quarter earnings report released toward the end of the month.
The big-ticket item that seems to have lit on fire underneath Vertex's stock last month is the immense growth within the company's core cystic fibrosis franchise over the past year. Per its Q4 earnings report and investor presentation at J.P. Morgan, for example, Vertex reported that its cystic fibrosis revenues -- emanating from the two FDA-approved drugs Orkambi and Kalydeco -- grew by an astounding 71% to $1.7 billion in 2016.
Adding fuel to the fire, Vertex also said it expects this red-hot sales growth to continue this year, with total cystic fibrosis revenues forecast to come in between $1.79 billion and $2.01 billion for full-year 2017.
Although it's not unusual for the market to pay top dollar for orphan drugmakers, Vertex's hefty price-to-sales ratio of 13.0 is fairly rich, even for a rare-disease specialist. Viewed this way, the market seems to be baking in additional approvals for Vertex's cystic fibrosis franchise in the near term, and/or perhaps counting on a buyout at a substantial premium. As neither of these scenarios is exactly a slam-dunk, I think it might be better to look elsewhere for more attractively priced vehicles as a way to gain exposure to the high-growth biotech space.